Sorafenib and Cellulitis - a phase IV clinical study of FDA data

Summary:

Cellulitis is reported as a side effect among people who take Sorafenib (sorafenib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Everolimus, and have Hepatocellular carcinoma.

The phase IV clinical study analyzes which people have Cellulitis when taking Sorafenib. It is created by eHealthMe based on reports of 3,194 people who have side effects when taking Sorafenib from the FDA, and is updated regularly.

What is Sorafenib?

Sorafenib has active ingredients of sorafenib. eHealthMe is studying from 3,201 Sorafenib users. Check the latest studies of Sorafenib.

What is Cellulitis?

Cellulitis (infection under the skin) is found to be associated with 2,080 drugs and 2,338 conditions by eHealthMe. Check the latest studies of Cellulitis.

On Jul, 20, 2026

3,194 people reported to have side effects when taking Sorafenib.
Among them, 19 people (0.59%) have Cellulitis.

Among these 19 people:

How long have people been on Sorafenib when they have Cellulitis? *

What is the gender of people who have Cellulitis when taking Sorafenib? *

female: 62.5 %
male: 37.5 %

What is the age of people who have Cellulitis when taking Sorafenib? *

What are other drugs people take besides Sorafenib? *

What are other side effects people have besides Cellulitis? *

Febrile Neutropenia (fever with reduced white blood cells): 8 people, 42.11%
Neutropenic Sepsis (whole body infection is caused by a condition in which the number of white blood cells (called neutrophils) in the blood is low. neutrophils help the body to fight infection): 5 people, 26.32%
Colitis (inflammation of colon): 5 people, 26.32%
Pneumonia: 4 people, 21.05%
Oedema (fluid collection in tissue): 4 people, 21.05%
Pneumonia Bacterial (pneumonia associated with bacterial infection): 4 people, 21.05%
Oedema Peripheral (superficial swelling): 3 people, 15.79%
Thrombotic Microangiopathy (a pathology that results in thrombosis in capillaries and arterioles, due to an endothelial injury): 3 people, 15.79%
High Blood Pressure: 3 people, 15.79%
Gastrointestinal Toxicity (damage to digestive tract by any substance): 3 people, 15.79%

What are the existing conditions these people have? *

Hepatocellular Carcinoma (liver cancer): 4 people, 21.05%
Acute Myeloid Leukaemia Recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent): 3 people, 15.79%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 15.79%
Neoplasm Malignant (cancer tumour): 2 people, 10.53%
Gastrointestinal Stromal Tumor: 2 people, 10.53%
Thyroid Cancer: 1 person, 5.26%
Sarcoma (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues): 1 person, 5.26%
Ovarian Cancer (cancer of ovary): 1 person, 5.26%
Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 1 person, 5.26%
Bone Marrow Oedema (inflammation that causes much than the needed fluid in a bone): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Sorafenib and have Cellulitis?

- Check whether Cellulitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sorafenib:

Sorafenib (3,201 reports)

Cellulitis treatments and more:

Cellulitis (75,290 reports)

Browse all side effects of Sorafenib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cellulitis:

Cellulitis (2,080 drugs)

Browse all the conditions that are associated with Cellulitis:

Cellulitis (2,338 conditions)

Related publications that referenced our studies

Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .
Musri FY, Mutlu H, K?vrak Salim D, Karakurt Ery?lmaz M, ?nal B, Tural D, ?enol Co?kun H, "Sorafenib-induced severe urticaria in a patient with hepatocellular cancer", Journal of Oncology Pharmacy Practice, 2016 Jan .
Yaylaci S, Yilmaz EU, Guclu E, Kumsar NA, Tamer A, Karabay O, "Clozapine-Induced Febrile Neutropenia and Cellulitis", Turkish journal of emergency medicine, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on sorafenib (the active ingredients of Sorafenib) and Sorafenib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.